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IMPORTANCE Although many classes of oral glucose-lowering medications have been
approved for use, little comparative effectiveness evidence exists to guide initial selection of
therapy for diabetes mellitus.
OBJECTIVE To determine the effect of initial oral glucose-lowering agent class on subsequent
need for treatment intensification and 4 short-term adverse clinical events.
DESIGN, SETTING, AND PARTICIPANTS This study was a retrospective cohort study of patients
who were fully insured members of Aetna (a large national health insurer) who had been
prescribed an oral glucose-lowering medication from July 1, 2009, through June 30, 2013.
Individuals newly prescribed an oral glucose-lowering agent who filled a second prescription
for a medication in the same class and with a dosage at or above the World Health
Organization’s defined daily dose within 90 days of the end-of-day’s supply of the first
prescription were studied. Individuals with interim prescriptions for other oral
glucose-lowering medications were excluded.
EXPOSURES Initiation of treatment with metformin, a sulfonylurea, a thiazolidinedione, or a
dipeptidyl peptidase 4 inhibitor.
MAIN OUTCOMES AND MEASURES Time to addition of a second oral agent or insulin, each
component separately, hypoglycemia, other diabetes-related emergency department visits,
and cardiovascular events.
RESULTS A total of 15 516 patients met the inclusion criteria, of whom 8964 (57.8%) started
therapy with metformin. In unadjusted analyses, use of medications other than metformin
was significantly associated with an increased risk of adding a second oral agent only, insulin
only, and a second agent or insulin (P < .001 for all). In propensity score and
multivariable-adjusted Cox proportional hazards models, initiation of therapy with
sulfonylureas (hazard ratio [HR], 1.68; 95% CI, 1.57-1.79), thiazolidinediones (HR, 1.61; 95% CI,
1.43-1.80), and dipeptidyl peptidase 4 inhibitors (HR, 1.62; 95% CI, 1.47-1.79) was associated
with an increased hazard of intensification. Alternatives to metformin were not associated
with a reduced risk of hypoglycemia, emergency department visits, or cardiovascular events.
CONCLUSIONS AND RELEVANCE Despite guidelines, only 57.8% of individuals began diabetes
treatment with metformin. Beginning treatment with metformin was associated with
reduced subsequent treatment intensification, without differences in rates of hypoglycemia
or other adverse clinical events. These findings have significant implications for quality of life
and medication costs.
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W ith approximately 29 million Americans affected andannual costs upward of $176 billion, diabetes melli-tus remains a national public health priority.1 Orga-
nizations such as the American Diabetes Association2 and the
American College of Physicians,3 as well as guidelines com-
missioned by the Agency for Healthcare Research and Quality,4
advocate metformin as the initial pharmacologic agent for glu-
cose-lowering therapy in type 2 diabetes. Despite this, gaps re-
main in the evidence base for this recommendation, particu-
larly with regard to newer glucose-lowering medication.5-8
Long-term data on the use of metformin as a first-line agent
to prevent diabetes complications comes largely from a single
study.5 Data used for drug approval and comparison of oral
glucose-lowering medications consist primarily of analyses as-
sessing the effect of the available medications on intermediate
physiological outcomes, most notably hemoglobin A1c.9 Given
the large number of agents that are now available and the increas-
ing use of newer classes, such as dipeptidyl peptidase 4 (DPP-4)
inhibitors,10 there is an urgent need to clarify differences among
the available therapies. Particularly relevant are patient-centric
outcomes, such as the need to intensify treatment with a second
oral agent or insulin to achieve a hemoglobin A1c goal; this ap-
proach can reduce patient quality of life by the same amount as
diabetes complications.11,12 In addition, because the effect of
medicationsinpreventingdiabetescomplicationsmaytakeyears
to become apparent, differences in short-term adverse events,
such as hypoglycemia and emergency department visits, may be
particularly relevant for patients initiating therapy and their phy-
sicians, although these differences have been insufficiently as-
sessed. We sought to determine the effect of the initial oral
glucose-lowering agent class on subsequent treatment intensi-
fication and 4 short-term adverse clinical events.
Methods
Setting and Data Source
The Brigham and Women’s Hospital Institutional Review Board
approved the study. Informed consent was not required for this
secondary data analysis. We used a limited data set of medical
and prescription claims data for commercial, fully insured mem-
bers of Aetna, a large national health insurer, to create a cohort
of patients who were prescribed an oral glucose-lowering medi-
cation from July 1, 2009, through June 30, 2013. These data con-
tainedcompletepaidclaimsforallprocedures,physicianencoun-
ters, hospitalizations, and filled prescriptions (including dose
dispensedandamountspaidbytheinsurerandpatient)andwere
linked to eligibility data that included patient age, sex, and zip
code of residence. Aggregate data on socioeconomic status, race/
ethnicity, and educational attainment were obtained by linking
zip code of residence with data from the 2010 US Census, which
specified the median household income and the distribution of
race/ethnicity and educational attainment of the population for
each zip code tabulation area.
Study Cohort
We created a cohort of individuals newly initiating use of an
oral glucose-lowering agent during the study period by iden-
tifying patients who filled a prescription for metformin, a sul-
fonylurea, a thiazolidinedione, or a DPP-4 inhibitor who had
not filled a prescription for any oral glucose-lowering medi-
cation in the previous 180 days. Because few patients initi-
ated therapy with a meglitinide (n = 88) or an α-glucosidase
inhibitor (n = 8), we excluded these patients from our sample.
Because glucagon-like peptide 1 agonists, such as exenatide,
were not approved as monotherapy at the beginning of the
study period13 and because they can be used off-label for weight
loss, we excluded these agents as a category of initial treat-
ment. A complete list of the agents included in each class is
presented in eTable 1 in the Supplement. The date of the pa-
tient’s first eligible prescription was defined as his or her in-
dex date. All patients were required to have maintained con-
tinuous insurance eligibility for at least 180 days before the
index date.
To ensure that our cohort represented individuals who tol-
erated the therapy that they had started, analogous to the
run-in period in a clinical trial, we restricted our analysis to pa-
tients who filled a second prescription for a medication in the
same class within 90 days of the end-of-day’s supply of the first
and had no filled prescriptions for other oral glucose-
lowering medications in the interim. As a result, we excluded
patients who began taking 2 different medications simultane-
ously (including combination therapy) or who had a second
medication added to their first shortly after treatment initia-
tion. To ensure comparison of therapeutically effective and
equivalent doses across medications and also to make op-
tions for dosage increase before adding another medication
more similar, we required the dose of each patient’s second
filled prescription to be at or above the World Health Organi-
zation’s defined daily dose14 for the medication. If a patient
had more than one eligible episode of treatment initiation dur-
ing the study period, we considered only the first. We calcu-
lated that we had greater than 80% power to detect a 5% dif-
ference in intensification event-free survival.
Outcomes
Our primary outcome was time to treatment intensification, de-
fined as the initiation of use of another class of oral glucose-
lowering medication (including glucagon-like peptide 1 ago-
nists, even though these are injectable) or insulin (eTable 1 in
the Supplement). We also looked at time to intensification with
either of these separately. Secondary outcomes included time
to composite cardiovascular event (defined as a new diagnosis
of coronary heart disease, congestive heart failure, unstable an-
gina, ischemic stroke, acute myocardial infarction, or a revas-
cularization procedure, based on International Classification of
Diseases, Ninth Revision [ICD-9] and Current Procedural Termi-
nology codes), congestive heart failure alone, an emergency de-
partment visit or hospital admission for hypoglycemia, and any
other diabetes-related emergency department visit.15 To avoid
issues of immortal time bias, follow-up began when the sec-
ond prescription of the index medication was filled.
Covariates
We considered several factors that occurred in the 180 days be-
fore each patient’s index date that may have influenced the re-
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ceipt of the index drug class or the study end points. These fac-
tors included age, sex, copayment amount for the index
prescription, the presence of specific conditions assessed using
ICD-9 codes (chronic kidney disease, coronary heart disease,
ischemic stroke, congestive heart failure, chronic obstructive
pulmonary disease or asthma, depression, hypertension, and
atrial fibrillation), the number of medications taken, the num-
ber of hospitalizations, and the number of physician visits. We
also calculated a combined comorbidity score that combined
conditions from the Charlson and Elixhauser measures.16 Be-
cause individual-level race/ethnicity, educational attain-
ment, and income data were not available, we used zip code–
based indicators from the 2010 US Census to account for some
of the compositional and contextual effects of these factors.
Statistical Analysis
We first performed descriptive statistical analysis and unad-
justed comparisons using χ2 tests for binary variables and analy-
sis of variance for continuous variables. We created a multi-
nomial propensity score using all of the covariates listed above
to estimate the probability that a patient’s initial medication
was metformin, the index drug class with the largest share of
new patients.17
To evaluate the association of the class of oral glucose-
lowering agent on our study outcomes, we first plotted Kaplan-
Meier curves and evaluated differences in survival with log-
rank tests. We then constructed Cox proportional hazards
models adjusting for all covariates, as well as the propensity
score, and tested for violations of the proportional hazards as-
sumption using Martingale residuals. Some crossing of haz-
ards was observed in Kaplan-Meier plots among the nonmet-
formin drug classes. To address this, we repeated our analyses
after adding a time-varying interaction for the index drug class,
considering time dichotomized as 1 year or less vs more than
1 year from date of initiation.
We conducted several additional sensitivity analyses to as-
sess the robustness of our results. Because the standard ICD-9
code–based diabetes definition (ICD-9: 250.x 2 outpatient or 1
inpatient diagnosis of diabetes) is relatively insensitive,18,19 our
primary analysis included all patients who started taking an
oral glucose-lowering agent. To check robustness, we fit mod-
els after restricting the cohort to patients with a recorded dia-
betes diagnosis in the 180 days before the index date. This ap-
proach also accounts for off-label, nondiabetes use of
metformin, such as for prediabetes or weight loss.
Second, we studied the association of initial oral glucose-
lowering drug class on cardiovascular outcomes among the sub-
set of patients who had no history of cardiovascular disease be-
fore starting use of an oral glucose-lowering agent. We
additionally redefined the cardiovascular outcome to exclude
revascularization because this procedure is often discretion-
ary. Third, to ensure we were evaluating patients who were add-
ing medications, as opposed to merely switching therapies, we
restricted our cohort to patients with the index medication on
hand at the time of intensification, defined as patients with sup-
ply continuing past the date of intensification.
Fourth, to assess whether patients had the primary out-
come of treatment intensification as a result of nonadher-
ence to their index drug rather than the clinical necessity of
better glycemic control, we examined 1-year adherence to the
index drug among patients with 12 months or more of con-
tinuous eligibility after the index date, with adequate adher-
ence defined as possession of medication for 80% of days or
more.
Results
Overall, 15 516 patients met the inclusion criteria as new ini-
tiators of oral glucose-lowering medications (eFigure 1 in the
Supplement). A total of 8964 patients (57.8%) initiated met-
formin therapy, with 3570 (23.0%) starting sulfonylurea
therapy, 948 (6.1%) starting thiazolidinedione therapy, and
2034 (13.1%) starting therapy with DPP-4 inhibitors (Table 1).
Across all medication categories, the mean age of patients was
52 years, and 7285 (47.0%) were women. Compared with us-
ers of other medication classes, those prescribed metformin
were younger, more likely to be women, and less likely to have
chronic kidney disease. The zip code–level indicators of edu-
cational attainment, income, and race/ethnicity were similar
across medication classes. Out-of-pocket spending for the fill-
ing of the initial prescription was significantly higher for DPP-4
inhibitors and thiazolidinediones (P < .001). Median fol-
low-up was similar for metformin (388 days), sulfonylureas (382
days), and DPP-4 inhibitors (376 days) but longer for thiazoli-
dinedione initiators (429 days) (P < .001).
Treatment Intensification
Rates of treatment intensification by drug class were signifi-
cantly different: 2198 patients (24.5%) prescribed metformin
required a second oral agent, whereas 1323 of 3570 patients
(37.1%) prescribed a sulfonylurea, 375 of 948 patients (39.6%)
prescribed a thiazolidinedione, and 736 of 2034 patients (36.2%)
prescribed a DPP-4 inhibitor did (P < .001) (Table 2). A total of
461 patients (5.1%) prescribed metformin later added insulin,
whereas 326 patients (9.1%) prescribed a sulfonylurea, 113 pa-
tients (5.6%) prescribed DPP-4 inhibitors, and 59 patients (6.2%)
prescribed thiazolidinediones did. Among metformin pa-
tients who added an oral agent, 1160 (52.8%) added a sulfo-
nylurea. For all other medication classes, metformin was the
most commonly prescribed oral agent for treatment intensi-
fication. Among patients who initiated therapy with a sulfo-
nylurea and intensified to a second oral agent, 893 (67.5%) in-
tensified to metformin. Similarly, 183 patients (48.8%) who
started taking a thiazolidinedione and then added a second oral
agent added metformin, as did 330 patients (44.8%) who
started taking a DPP-4 inhibitor.
In unadjusted analyses, patients who started taking sul-
fonylureas, DPP-4 inhibitors, and thiazolidinediones were more
likely than those who started taking metformin to add an oral
agent or insulin, a second oral agent only, or insulin only
(P < .001 for all 3 comparisons) (Figure). These results re-
mained significant in multivariable Cox proportional hazards
models, with sulfonylurea (hazard ratio [HR], 1.68; 95% CI, 1.57-
1.79), thiazolidinedione (HR, 1.61; 95% CI, 1.43-1.80), and DPP-4
inhibitor (HR, 1.62; 95% CI, 1.47-1.79) all associated with an in-
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creased hazard of addition of an oral agent or insulin com-
pared with metformin (Table 3). The results were similar when
considering only the addition of a second oral drug class or only
the addition of insulin. When considering that the HR may vary
by period, results revealed an even larger hazard of intensifi-
cation compared with metformin after the first year (sulfonyl-
urea: HR, 1.76; 95% CI, 1.51-2.06; thiazolidinedione: HR, 2.08;
95% CI, 1.66-2.60; DPP-4 inhibitor: HR, 2.06; 95% CI, 1.69-
2.51), whereas the hazard of intensification in the first vs later
years was similar to the non–time-varying results (sulfonyl-
urea: HR, 1.66; 95% CI, 1.54-1.78; thiazolidinedione: HR, 1.50;
95% CI, 1.31-1.71; DPP-4 inhibitor: HR, 1.54; 95% CI, 1.39-1.72)
(eTable 2 in the Supplement).
Secondary Outcomes
Sulfonylurea use was associated with an increased hazard of
composite cardiovascular events (HR, 1.16; 95% CI, 1.04-1.29)
and congestive heart failure (HR, 1.19; 95% CI, 1.10-1.28)
(Table 3). There was no evidence of differential hazards for
composite cardiovascular event with thiazolidinedione. Al-
though the HR for congestive heart failure with thiazolidin-
ediones was 1.08, this increase was not statistically signifi-
cant (95% CI, 0.93-1.26).
Only 72 patients had a diagnosis of hypoglycemia re-
corded during follow-up. After adjustment for propensity score
alone, sulfonylurea was associated with increased risk of
hypoglycemia (HR, 2.71; 95% CI, 1.58-4.66), whereas thiazo-










(n = 948) P Valueb





12.66 (14.83) 10.78 (8.33) 52.23 (55.42) 46.31 (57.37) <.001
Female sex 4504 (50.3) 1510 (42.3) 950 (46.7) 321 (33.9) <.001
Mean age, y 49.9 55.1 56.4 56.2 <.001
Age group, y
18-54 5447 (60.8) 1603 (44.9) 810 (39.8) 384 (40.5)
<.00155-64 2802 (31.3) 1372 (38.4) 895 (44.0) 407 (42.9)
≥65 715 (8.0) 595 (16.7) 329 (16.2) 157 (16.6)
Median household
income by zip code, $
<50 000 2609 (29.1) 1240 (34.7) 503 (24.7) 290 (30.6)
<.00150 000-99 999 5658 (63.1) 2127 (59.6) 1344 (66.1) 599 (63.2)
≥100 000 679 (7.6) 198 (5.6) 183 (9.0) 57 (6.0)
Non-Hispanic black 18 (12.7) 21 (15.6) 18 (12.6) 19 (13.1) <.001
High school education
or more




145 (1.6) 230 (6.4) 104 (5.1) 50 (5.3) <.001
Coronary artery
disease
464 (5.2) 340 (9.5) 209 (10.3) 84 (8.9) <.001
Ischemic stroke 102 (1.1) 62 (1.7) 36 (1.8) 17 (1.8) .01
Congestive heart
failure
104 (1.2) 112 (3.1) 52 (2.6) 14 (1.5) <.001
Asthma or COPD 527 (5.9) 231 (6.5) 150 (7.4) 45 (4.8) .02
Dementia 11 (0.1) 7 (0.2) 1 (0.1) 2 (0.2) .46
Depression 441 (4.9) 129 (3.6) 94 (4.6) 47 (5.0) .02
Hypertension 3699 (41.3) 1694 (47.5) 1156 (56.8) 478 (50.4) <.001












0.00 (0.89) 0.23 (1.38) 0.11 (1.32) 0.05 (1.17) <.001
Propensity score,
mean (SD)
0.65 (0.15) 0.59 (0.15) 0.32 (0.23) 0.38 (0.23) <.001
Abbreviations: COPD, chronic
obstructive pulmonary disease;
DPP-4, dipeptidyl peptidase 4;
ICD-9, International Classification of
Diseases, Ninth Revision.
a Data are presented as number
(percentage) of patients at baseline
unless otherwise indicated.
b χ2 Test for binary variables, analysis
of variance for continuous variables,
and Kruskal-Wallis test for median
days of follow-up.
c Sum of copayment, coinsurance,
and deductible.
d After baseline refers to patients
who had a diabetes diagnosis in the
180 days after the index date but
not in the period before baseline.
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lidinediones (HR, 0.36; 95% CI, 0.08-1.64) and DPP-4 inhibi-
tors (HR, 0.37; 95% CI, 0.11-1.17) were not. No statistically sig-
nificant difference was found among drug classes with regard
to nonhypoglycemia diabetes-associated emergency depart-
ment visits (Table 3).
All results were robust to the sensitivity analyses (eTable
3 in the Supplement). Overall, patients with a diabetes diag-
nosis recorded before the index date had a greater risk of in-
tensification compared with metformin than the full cohort.
Patients with no history of cardiovascular disease and treated
initially with DPP-4 inhibitors or sulfonylureas had a risk of car-
diovascular events similar to the full cohort, whereas the risk
for those taking thiazolidinediones was attenuated. Among pa-
tients with index medication on hand at the time of addition
of a second oral agent, the hazard of intensification was es-
sentially unchanged compared with the full cohort.
Finally, in a subset of patients with at least 12 months of
follow-up, 4776 patients (28.2%) prescribed metformin had ad-
equate adherence compared with 1880 patients (28.9%) tak-
ing sulfonylurea (P = .45), 532 patients (32.5%) taking thiazo-
Table 2. Intensification to Additional Oral Glucose-Lowering Agent
Agent Added by Index Class No. (%) of Patients Who Added an Oral Agent
Metformin
Sulfonylurea 1160 (52.8)
DPP-4 inhibitor 405 (18.4)
Combination 246 (11.2)
GLP-1 receptor agonist 190 (8.6)
Thiazolidinedione 170 (7.7)
Meglitinide 17 (0.8)








GLP-1 receptor agonist 41 (5.6)
Meglitinide 14 (1.9)




DPP-4 inhibitor 181 (13.7)
Combination 122 (9.2)
Thiazolidinedione 79 (6.0)
GLP-1 receptor agonist 36 (2.7)
Meglitinide 9 (0.7)






DPP-4 inhibitor 43 (11.5)
GLP-1 receptor agonist 15 (4.0)
Meglitinide 4 (1.1)
α-Glucosidase inhibitor 1 (0)
Total 375/948 (39.6)
Abbreviations: DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1.
















































































A, Unadjusted time to intensification to second oral agent or insulin (P < .001).
B, Intensification to second oral agent only. C, Intensification to insulin only.
Log-rank test P <.001. DPP-4 indicates dipeptidyl peptidase 4.
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lidinedione (P = .02), and 1063 patients (41.6%) taking DPP-4
inhibitors (P < .001).
Discussion
We evaluated whether class of oral glucose-lowering agent first
prescribed to a patient with diabetes influenced patients’ like-
lihood of treatment intensification and short-term harms, such
as cardiovascular events, emergency department visits, and
hypoglycemia. We found that patients initially prescribed met-
formin were significantly less likely to require treatment in-
tensification than those who started taking sulfonylureas, thia-
zolidinediones, or DPP-4 inhibitors. Furthermore, we found
no compensatory advantages for other agents with regard to
other short-term clinical outcomes. In fact, we found that sul-
fonylureas, the second most commonly prescribed initial class,
were associated with increased risk of cardiovascular events
and hypoglycemia.
Previous comparative effectiveness studies3,4,9 in diabe-
tes have largely focused on intermediate clinical end points,
such as reducing hemoglobin A1c, and found little difference
between medication classes with respect to this outcome. In
its most recent comparative effectiveness report, the Agency
for Healthcare Research and Quality4 did not consider issues
of durability of glycemic response and regimen intensity, which
it said “may best be addressed using long-term well-designed
observational studies.” In the A Diabetes Outcomes Progres-
sion Trial (ADOPT) study,20 rosiglitazone, a thiazolidinedi-
one no longer in widespread use in the United States21 and not
marketed in Europe,22 was superior to metformin and gly-
buride with regard to time until fasting plasma glucose level
exceeded 180 mg/dL (to convert to millimoles per liter, mul-
tiply by 0.0555), which could translate into reduced need for
additional glucose-lowering agents. In contrast, we found that
initial therapy with thiazolidinediones, largely pioglitazone,
was associated with an increased hazard of adding additional
therapeutic agents. Our results likely differ from those of
ADOPT because, as opposed to considering only glucose level,
in real-world practice, treatment intensification decisions may
involve multiple considerations, including cost, safety, toler-
ability, patient preference, and effectiveness. Thus, although
some have suggested that a treatment strategy that includes
thiazolidinediones as insulin-sensitizing agents could delay the
need for treatment intensification,23 we found no evidence of
this when compared with metformin. In contrast, our data sup-
port previously raised concerns23 that DPP-4 inhibitors, de-
spite their increasing popularity, may not be potent enough to
delay treatment intensification significantly. These findings
may be particularly relevant because the greater adherence to
DPP-4 inhibitor and thiazolidinedione medication use that we
observed should, if anything, have reduced treatment inten-
sification.
Our study focused on treatment intensification, which can
be aversive to patients11,12,24 and inherently associated with in-
creased adverse effects and costs. Although we agree that pa-
tient education is important, particularly with the message that
treatment intensification is part of the normal progression of
diabetes, and does not represent a personal failure, our study
provides useful information to physicians to guide selection
of initial oral glucose-lowering agent because delaying treat-
ment intensification when safe to do so offers benefits to pa-
tients and the health care system. This finding is particularly
relevant because patients and physicians have little informa-
tion at their disposal when deciding about initial diabetes
therapy, especially for many of the newer agents. Metformin
has been well documented to reduce end-organ damage in pa-
tients with diabetes,5,25 as opposed to most of the newer oral
agents, which generally lack evidence of their capacity to pro-
tect patients from macrovascular or microvascular complica-
tions of diabetes.4 Thus, our data support guideline recom-
mendations that metformin be used as the first-line therapy
for patients with diabetes.2
Our study adds to an increasing body of evidence that sug-
gests that sulfonylureas may be associated with increased risk
of cardiovascular disease. In particular, this study adds data
on women, compared with a prior study26 based in the Veter-
ans Affairs system that found an adjusted increase of 2.2 car-
diovascular disease events per 1000 users of sulfonylureas com-
pared with metformin. In contrast to an earlier study,27 we
found no evidence that thiazolidinediones increased the rate
of a new diagnosis of congestive heart failure. This lack of evi-
dence may be partly due to a small sample size of initiators of
thiazolidinedione therapy in our analysis because we ob-
served an elevated HR of clinically meaningful magnitude but
not of statistical significance. In addition, in the face of wide-
Table 3. Hazard Ratios (95% CIs) for Primary Therapy Intensification and Secondary Clinical Outcomesa
Index Drug Class Metformin DPP-4 Inhibitor Sulfonylurea Thiazolidinedione
Primary outcome
Therapy intensification:
second oral agent or
insulin
1.0 [Reference] 1.62 (1.47-1.79)b 1.68 (1.57-1.79)b 1.61 (1.43-1.80)b
Therapy intensification:
second oral agent only
1.0 [Reference] 1.68 (1.52-1.87)b 1.65 (1.54-1.77)b 1.62 (1.44-1.83)b
Therapy intensification:
insulin only
1.0 [Reference] 1.35 (1.06-1.74) 1.73 (1.49-2.00)b 1.24 (0.93-1.67)
Secondary outcome
Diabetes-related ED visit 1.0 [Reference] 1.04 (0.79-1.36) 1.23 (1.04-1.46) 1.24 (0.91-1.70)
Composite cardiovascular
outcomec
1.0 [Reference] 0.99 (0.85-1.16) 1.16 (1.04-1.29) 1.05 (0.87-1.27)
Congestive heart failure 1.0 [Reference] 1.13 (1.00-1.28) 1.19 (1.10-1.28)b 1.08 (0.93-1.26)
Abbreviations: DPP-4, dipeptidyl
peptidase 4; ED, emergency
department.
a Values adjusted for age, sex, index
copayment, race, income,
educational attainment, number of
medications, number of physician
visits, number of hospitalizations,
specific conditions, combined
comorbidity score, and propensity
score.
b Significant at P < .001.
c New diagnosis of coronary heart
disease, congestive heart failure,
unstable angina, ischemic stroke,
acute myocardial infarction, or a
revascularization procedure.
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spread warnings about this adverse event with thiazolidinedi-
one use, physicians may now guide high-risk patients away
from this medication class.28 The lack of other differences in
outcomes among medication classes is to be expected given
the relatively short follow-up timeframe of this study.
Our study has several notable strengths. We evaluated a
large, nationally representative data set of insured patients,
which provides evidence regarding real-world clinical prac-
tice but also restricts some demographic heterogeneity to help
provide a more equal comparison. We had access to accurate
records regarding all filled prescriptions, not just prescribing
records. We used the defined daily dose to ensure compari-
son of therapeutically equivalent medication doses. Finally,
although changes in oral medication could conceivably be re-
lated to formulary issues, treatment with insulin unequivo-
cally represents intensification, especially given widespread
patient and physician resistance to beginning insulin therapy.24
Our results should be interpreted in the context of sev-
eral methodologic limitations. We did not have access to the
reason for initial medication selection in this data set, which
raises the possibility of confounding by indication. Although
the propensity score method we used accounts for the mea-
sured differences among the groups that we present, unmea-
sured confounding may remain. Such confounding could in-
clude controversy over diabetes treatments, different
prescribing patterns and demographic differences among phy-
sicians, history of gastrointestinal disorders, patient weight,
and gastrointestinal adverse events. The main contraindica-
tion for metformin is reduced renal function, and it is reassur-
ing that less than 10% of patients who used medication classes
other than metformin met criteria for chronic kidney disease
and that the hazard of treatment intensification persisted even
after adjustment for this diagnosis. In addition, patients who
intensified to a second oral agent usually intensified to met-
formin, suggesting that there was no contraindication. Be-
cause we required all patients in the cohort to have filled 2 pre-
scriptions for their index medication at therapeutically
equivalent doses, intolerance of metformin was unlikely to
have driven medication selection. Because we did not have
laboratory data, we do not know the level of hyperglycemia
at baseline or when intensification occurred. Differences in
these attributes across classes, although unlikely by the na-
ture of our study design, could have influenced our results. For
this study, we required each patient to fill a second prescrip-
tion at a therapeutically effective dose to allow for a fair com-
parison of different agents. Although this approach enhances
internal validity, it may also produce selection bias. However,
because the question of which initial agent to select to delay
future treatment intensification is most relevant for those pa-
tients who can tolerate effective doses of their initial agent, the
sample we analyzed is likely similar to those patients for whom
the results are most applicable in general practice. For the hy-
poglycemia outcome, we were unable to evaluate episodes of
hypoglycemia that did not result in emergency department vis-
its; thus, we only have data on the most severe cases of hypo-
glycemia. A final limitation of our analysis is that we lacked
access to information regarding glycemic control among pre-
scriber patient populations. Different prescribing patterns
among prescribers may have influenced the decision to inten-
sify treatment.
Conclusions
These findings indicate that the initial use of metformin was
significantly associated with a lower risk of subsequent treat-
ment intensification compared with other oral agents. These
other agents offered no compensatory benefits over metfor-
min with regard to the adverse events we evaluated. In fact,
we found that sulfonylurea was associated with increased
harms. Because underuse of metformin may lead to impor-
tant harms and costs in the treatment of patients with diabe-
tes, multilevel interventions to increase prescribing quality may
be needed.
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Invited Commentary
Initial Therapy for Diabetes Mellitus
Jodi B. Segal, MD, MPH; Nisa M. Maruthur, MD, MHS
Berkowitz and colleagues1 assert that there is little compara-
tive effectiveness evidence to guide initial selection of therapy
for diabetes mellitus. They therefore conducted this rigorous
study to determine effects attributable to initial oral glucose-
lowering agents. With a retrospective cohort design using 4
years of recent claims data from a large national insurer, they
investigated outcomes from 4 classes of oral diabetes medi-
cations (metformin, sulfonylureas, thiazolidinediones, and
dipeptidyl peptidase 4 inhibitors). In their adjusted models,
initiation of therapy with a
sulfonylurea, thiazolidinedi-
one, or dipeptidyl phospha-
tase 4 inhibitor was associ-
ated with an increased hazard of treatment intensification
(addition of another drug) relative to first therapy with met-
formin, without greater clinical benefits (and often more short-
term adverse events). The authors noted that only 57.8% of in-
dividuals in their data set began pharmaceutical management
of their diabetes with metformin. This study understandably
omitted the newest class of medications—the sodium-
dependent glucose transporter 2 inhibitors—because the first
drug was not approved in the United States until March 2013.
Less understandable is the exclusion of injectable medica-
tions from the glucagon-like peptide 1 agonist class despite
their approval for use as monotherapy and availability since
2005.
This meticulously conducted study, however, adds mod-
estly to what is already known on this topic. Existing evi-
dence is strong on the use of metformin as first-line therapy.
Although the choice of adjunctive agent for treatment inten-
sification remains uncertain (prompting the Glycemia Reduc-
tion Approaches in Diabetes: A Comparative Effectiveness
Study, under way since 2013), first-line therapy should be met-
formin in patients without contraindications. The Agency for
Healthcare Research and Quality has commissioned 2 reviews2,3
on the comparative effectiveness of oral therapy for treat-
ment of type 2 diabetes—the first in 2007 and the second in 2011.
An update of this review is under way, with results expected
in spring 2015. As early as the first review, it was clear that the
comparative effectiveness literature supports first-line treat-
ment with metformin; metformin is equivalent or superior to
most other drugs in lowering hemoglobin A1c levels but with
less weight gain and less hypoglycemia than most.3 The ef-
fect on longer-term clinical outcomes remains uncertain; the
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study in JAMA Internal Medicine contributes little to this knowl-
edge base given that the median follow-up time was just lon-
ger than 1 year.
Guidelines published after the publication of the first Agency
for Healthcare Research and Quality systematic review, includ-
ing those from the American Diabetes Association, the Ameri-
can Association of Clinical Endocrinologists, the American Col-
lege of Endocrinology, the European Association for the Study
of Diabetes, and the UK National Institute for Health and Care
Excellence, largely recommend metformin as first-line therapy.4
The joint consensus statement from the American Association
of Clinical Endocrinologists/American College of Endocrinology5
described metformin as the “cornerstone of monotherapy” be-
cause of its safety and efficacy. However, 4 other drugs were also
recommended as possible first-line medication options in its
monotherapy algorithm. Thus, the superiority of metformin as
first-line therapy is not novel, although the outcome of treat-
ment intensification is not a commonly reported outcome and
may indeed be important to patients.
Incomplete conformity with guideline recommenda-
tions is well recognized. Recent work6 by the HMO Research
Network described initial therapy used by patients in health
maintenance organizations across the United States. This ret-
rospective cohort study6 included 241 327 patients from 11 US
health systems from 2005 through 2010. Within 6 months of
diabetes diagnosis, only 40% of patients had started taking
medication, although patients with higher hemoglobin A1c lev-
els were more likely to begin taking medication. Seventy-five
percent of the initial prescriptions were for metformin; it is un-
likely that 25% of the population had contraindications to its
use. The ideal percentage of patients whose initial prescrip-
tion is for metformin is a moving target; physicians, sup-
ported by evidence,7 are increasingly using metformin in pa-
tients with mild to moderate renal insufficiency who would
previously have been considered to have contraindications to
its use. The percentage of patients excluded from an attempt
at metformin therapy should be small.
As in the study by Berkowitz and colleagues, the health
maintenance organization researchers also examined the time
to intensification of therapy. Among 41 233 patients taking
medication, 33% and 45% had treatment intensified within 6
and 12 months after beginning their first medicine. This ini-
tial intensification was most often done with increased dos-
age of the first medication. The figure in the study by Berko-
witz et al shows, comparably, that roughly 25% of patients
initially using metformin and 40% of those using other medi-
cations intensified therapy in the first 12 months. Unlike in the
study by Berkowitz et al, Raebel and colleagues6 did not stratify
intensification by the initial therapy.
We wonder, however, about the choice of addition of medi-
cation as the only indicator of treatment intensification rather
than a dosage increase. Raebel and colleagues6 considered either
one to be an indicator of intensification. This consideration is
particularly germane to use of metformin because the slow ti-
tration of metformin typically reduces gastrointestinal ad-
verse effects. This slow increase of the dose over time may de-
lay the time until a second agent is added without indicating the
superiority of metformin. We note, as well, that the authors did
not have the necessary data (laboratory results) to confirm that
the delayed initiation of a second agent was due to sustained
good control with a single agent, but we do not think that a phy-
sician’s response to poor control would differ by drug.
The published evidence to date has not focused on the need
for intensification of therapy as an outcome, and the authors
of this new study appropriately cite literature on this patient-
centered outcome. We find this observation to be the most com-
pelling rationale for this article: that patients consider treat-
ment intensification to be failure. Although this statement has
implications for initial choice of therapy, it has greater impli-
cations for patient-physician communication about diabetes.
Although it is true in some patients that the need to add an ad-
ditional medication is due to their imperfect adherence to diet
and exercise or adherence to the first prescribed drug, in many
other patients it reflects the expected progression of disease and
worsening insulin sensitivity and declining β-cell function.
Whereas in hypertension management the use of several sub-
maximal doses of medication is supported by evidence and well
accepted by patients, this approach is not the case in diabetes
management. Reframing the addition of medication as a nec-
essary step for wellness and health maintenance may go a long
way toward patient acceptance of intensification as an unfor-
tunate but necessary part of good self-care.
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